Showing posts with label Pharmaceuticals. Show all posts
Showing posts with label Pharmaceuticals. Show all posts

Monday, 16 June 2014

According to a new market report published by Transparency Market Research "Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47 billion in 2018.

Browse the Pain Management Therapeutics Market Research report with full TOC at http://www.transparencymarketresearch.com/pain-management-therapeutics.html

The global pain management therapeutics market is expected to experience a decline in revenues at a CAGR of (5.5%) during the forecast period, mainly due to patent expirations of the leading branded drugs. Although the global incidence rates of cancer, diabetes and other debilitating diseases that cause various chronic pain conditions is on a rise, the decline in market revenue is inevitable due to generic incursion for the top pain management drugs. Moreover, lack of a strong pipeline of novel or combination drugs that could help restore the positive growth of the overall market is also expected to contribute to the overall decline in the global pain management therapeutics market.
Administration of analgesics is the first line of treatment for the management of acute as well as chronic pain conditions. Some of the factors driving the growth of this market include the favorable regulatory and healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010. Also, the economic and effective nature of treatment with therapeutics compared to other modes, such as neurostimulation devices and acupuncture, will continue to fuel the uptake of drugs in pain management.


The market for non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the largest share by revenue in 2011, of the total pain management therapeutics market by therapeutic class. This class comprises of some of the oldest known painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid) which are now commonly available as over-the-counter (OTC) medications, globally. However, the patent expiry of Celebrex (celecoxib) in 2013 is expected to negatively impact the market with a decline in revenues post patent expiry. The class of other non-narcotic analgesics consists of acetaminophen, sold as OTC drugs in the names of Tylenol, Panadol and Excedrin, and is expected to record the highest CAGR of 3.1% during the forecast period.

Browse all Pharmaceutical Market Research Reports @http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

North America was the largest regional market by revenue in 2011, due to the presence of one or more branded drugs belonging to each therapeutic class. However, the region is expected to record the lowest CAGR due to the looming patent expiries of these brands.
The market for generic formulations accounted for a larger share of the overall pain management therapeutics market in 2011, as against branded formulations. The market for branded pharmaceuticals was highly fragmented in 2011, with Pfizer, Inc., Purdue Pharma LP and Eli Lilly & Co. contributing to over 80% of the total market revenue. Other important players in this market include Endo Health Solutions, AstraZeneca PLC, Johnson & Johnson, and Merck & Co., Inc.

Friday, 13 June 2014

According to the latest market report published by Transparency Market Research "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018", the global liver diseases therapeutics market was worth USD 6.5 billion in 2011 and is expected to reach USD 10.9 billion in 2018, growing at a CAGR of 8.6% from 2012 to 2018. In the overall global market, anti-viral drugs are expected to create its lead position in terms of revenue generation by 2018. Anti-viral drugs will have a share of 32.7% of the global market followed by vaccines at 19.1% in 2018.

Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html 

The major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However side-effects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market.


Anti-viral drugs represent the largest market in the liver disease therapeutics, which is justified by the fact that many oral, direct-acting antiviral medications are in development phase for treating hepatitis C. Currently, anti-virals are only available for hepatitis B and C. However, many anti-viral hepatitis C pipeline drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate this market in near future.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html


This research is specially designed to estimate and analyze the demand for liver diseases therapeutics in global market. The research provides an in-depth analysis of the product sales, drugs class wise trend analysis and the major player pertaining to this market. High level analysis of the mentioned drug class of global liver diseases therapeutics market is performed and the report provides detailed analysis, comprehensive historical data and statistically tested forecast of the drug classes thus covered. Detailed qualitative information is given for different liver diseases and the application of different drugs as the treatment and therapy option.

Thursday, 12 June 2014

According to a new market report published by Transparency Market Research "Membrane separation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global membrane separation market was valued at USD 19.0 billion in 2012 and is expected to grow at a CAGR of 10.8% from 2013 to 2019, to reach an estimated value of USD 39.2 billion in 2019.

Browse the full Membrane separation Market Report at http://www.transparencymarketresearch.com/membrane-separation-market.html

The increasing demand for clean processed water and mandatory government regulation to provide clean drinking water is propelling the water processing industry at present. Membrane separation is one of the most popular methods used for cleaning water. Shifting from chemical to physical treatments of water is also a major driver as chemical treatments are perceived as an environmentally unclean technology with associated disposal costs. Additional awareness of water scarcity has influenced the demand for water reuse in water stressed areas. Governments and municipal authorities are increasingly waking up to the effects of environmental degradation on the economy. Mandatory adherence of certain environmental standards by the national government such as the Clean Water Act especially in areas with water scarcity have influenced the demand for better water treatment technology, including membrane separation technology.


Worldwide industrial expansion and growing population are propelling the demand for better water treatment technology, providing growth opportunity for the overall market of membrane separation technology. Additionally, the oil and petroleum industry is well established in countries such as Italy and Germany which involve membrane separation technology for liquid separation. Membrane separation technology is majorly divided under four major processes, microfiltration, ultrafiltration, nanofiltration and reverse osmosis. Microfiltration dominates the market with more than 35% global market share. Whereas water & wastewater dominates the end-user market with 36% global market shares in terms of uses. The global membrane separation market grew from USD 19.0 billion in 2010 to USD 21.2 billion in 2013.
European membrane market is expected to reach USD 13.8 billion in 2019. In 2012 water & wastewater sector was the major end-user of membrane separation technology and is expected to increase at a CAGR of 11.1% during 2013-19. The membrane separation technology market is fragmented with several players in the market supplying membrane separation to the end-users in the market.


Membrane separation is used by various sectors such as water and wastewater treatment and industrial and healthcare sectors. Most of the companies produce different types of membrane products such as microfiltration, nanofiltration, ultrafiltration and reverse osmosis and sell them globally. Major companies that are operating globally and manufacturing all four products are Koch Membrane Systems Inc., Pall Corporation, Merck Millipore, 3M Company, Degremont SA, Dow Chemical Company, GEA Filtration, Nitto Denko Corporation, Époque Water Technologies and Veolia Environnement.